Alnylam Pharmaceuticals: Clinical Trials & Research Profile
Biopharma Industry (Cambridge, MA) · Primary Focus: Rare Genetic, Women's Health, and Other
| Clinical Trial Metric | Verified Public Record |
|---|---|
| Organization Type | Consolidated Trial Sponsor |
| Institutional Sector & Location | Biopharma Industry (Cambridge, MA) |
| Primary Therapeutic Area | Rare Genetic, Women's Health, and Other |
| Active Phase II & III Studies | 13 active (9 recruiting now) |
| Total Tracked Studies (2018 to 2026) | 29 (18 with California sites) |
| Completed vs Early-Stopped Studies | 11 completed / 5 stopped (17.2% stop rate) |
| Median Closed Enrollment | 47 participants |
| FDA Drugs@FDA Original Approvals | 4 all-time (4 from 2018 to 2026) |
| Physical Hospital Site Disclosure | 100.0% named hospital slots |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Alnylam Pharmaceuticals across sibling Meru public-data platforms.
Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI -> · AI for Healthcare · Healthcare Price & Patent Cliff Crosswalk